Validation Of Predictive Biomarkers For T-DM1 Activity In HER2+ Breast Cancer
The antibody-drug conjugate trastuzumab emtansine (T-DM1; Kadcyla) extends the survival of HER2-positive metastatic breast cancer patients. However, both acquired and intrinsic resistance limit its effectiveness and there are no reliable biomarkers for predicting the tumour response to T-DM1. Applying advanced genetic methods, we have identified a panel of 612 genes that we hypothesise to be involved in T-DM1 resistance. Here, we propose to validate the pre-selected candidate genes to select those with the highest potential to modify T-DM1 activity. We will apply cellular and animal models to check how inactivation of these genes influences the response to T-DM1. Finally, we will correlate their activity with the oncologic response of breast cancer patients to T-DM1 therapy. In the long term, our work could be applied to identify breast cancer patients most likely to benefit from T-DM1 or those patients who are most likely to develop resistance.
Keep reading
View all
Can Functional MRI of the Brain help us understand Brain Fog in Women with Breast Cancer?
Up to 70% of women with breast cancer experience cognitive difficulties, but scientists still don't fully understand why this happens. Without a clear understanding of the underlying cause, it is d...
Exploring Better Breast Imaging for Women in Aotearoa New Zealand
Mammograms save lives by finding breast cancer early. But they do not work equally well for everyone.For women with very dense breast tissue, cancer can be harder to see on a standard mammogram. Th...
From Evidence to Action: Expanding the ‘Not a One-Size-Fits-All’ Breast Cancer Screening Model for Aotearoa New Zealand.
Breast cancer screening in Aotearoa New Zealand does not benefit all women equally. Many cancers are still found outside the national screening programme, and Māori and Pacific women can face delay...
